Pglyrp1 as sulcus protein marker for the detection of peri-implantitis
The method detects peri-implantitis through quantifying specific protein markers in sulcus fluid, addressing the lack of non-invasive diagnostics and enabling early detection for improved treatment.
Patent Information
- Application Number
- PCT/EP2026/063309
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Current methods for detecting peri-implantitis lack non-invasive, reliable diagnostic tools, as existing biomarkers are limited and invasive measurements only indicate the disease after it has progressed, limiting treatment options.
A method for detecting peri-implantitis by quantifying specific protein markers in sulcus fluid samples, such as PGLYRP1, UBE2V2, BPIFB2, LAMC2, ITGA6, and LAMA3, which are enriched or depleted compared to healthy samples, using techniques like ELISA and mass spectrometry.
Enables early and accurate detection of peri-implantitis, allowing for timely intervention and improving treatment outcomes by identifying specific protein marker signatures in sulcus fluid.
Smart Images

Figure EP2026063309_12112026_PF_FP_ABST
Abstract
Description
[0001] Sulcus protein markers for the detection of peri-implantitis
[0002] The present invention relates to a method, in particular an in vitro method, for a method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant, comprising detecting, and quantifying at least one protein marker in a sulcus fluid sample obtained from said subject that is enriched or depleted in the sample when compared to a sulcus fluid sample obtained from a healthy subject (H), a healthy implant (I) and / or a healthy tooth (T), wherein an enrichment of at least one protein marker as identified or wherein a depletion of at least one protein as identified detects a PI in said subject. Furthermore, the present invention relates to the application of the findings of the invention in the development of new anti-PI therapies and as well as to a kit for performing the above methods as well as respective uses thereof. Finally, improved anti-PI compounds or pharmaceutical compositions are provided.
[0003] Background of the invention
[0004] Around 12 million dental implants are inserted worldwide every year (1 million of them in Germany) (Albrektsson 2014, VDDI 2015). Long-term survival rates document that over 90 % of implants are still in situ. However, peri-implant inflammation with bone loss (peri-implantitis) is common, with a prevalence of up to 20 % within 10 years (Derks 2015). At present, it is assumed that the aetiology is determined by a microbial biofilm in a susceptible host. Prosthetic, surgical or biomechanical factors are discussed as an additional aetiological mechanism for peri-implant bone loss with varying degrees of evidence (Canullo et al. 2015, Albrektsson 2016, Fretwurst 2018). 50 % of implants become diseased within 3 years of implant placement and show a progressive course of disease, which can subsequently lead to implant loss (Derks 2016). There are currently no standardized treatment protocols and these are associated with high recurrence rates even after a decade of intensive research (Esposito et al. 2012, Derks COIR 2020). Drug therapies with a curative approach are not available.
[0005] Only invasive, non-specific measurements (peri-implant pocket depth measurement, radiographic peri-implant bone level) are available to detect manifest peri-implantitis(Schwarz, S3 guideline 2016). Early non-invasive diagnostic tools ("early detection") or parameters are lacking, as radiographic bone loss and probing depth only indicate peri-implantitis if the disease has already occurred, which limits treatment options. Microbiological diagnostics for peri-implant diseases are unspecific and cannot be used for diagnosis to date. In recent years, some biomarkers in the peri-implant sulcus fluid have mainly been examined using ELISA, spectrophotometry or flow cytometry (Alassy et al. 2019). Sulcus fluid is of particular interest here. Sulcus fluid refers to the fluid in the groove between the tooth (or implant) and the gum. Sulcus fluid must be distinguished from sputum. However, only a limited amount of proteins can be detected with these analytical methods and the functional composition of the sulcus fluid cannot be fully recorded, so that research in recent years has largely focused on a few a priori selected biomarkers that have not yet been validated for diagnostics. These include pro-inflammatory cytokines such as TNF, IL-1, IL-6, IL- 12, IL- 17, anti-inflammatory cytokines such as IL-4 and IL- 10, biomarkers of bone metabolism such as Receptor activator nuclear factor kappa-B ligand (RANKE), Receptor activator nuclear factor B (RANK), osteoprotegerin (OPG) and osteocalcin, as well as specific enzymes such as matrix metalloproteinases (MMP1, MMP8, MMP9, MMP13) and tissue inhibitor of metalloproteinases 1 and 2 (TIMP) are the focus of peri-implantitis research (Alassy et al. 2019, Iglhaut et al. 2021).
[0006] There is a clear interest in non-invasive methods for detecting peri-implantitis in contrast to healthy, non-inflamed implants.
[0007] KR20220022835A discloses a biomarker for diagnosing peri-implantitis, a composition for diagnosing peri-implantitis using the same, and a diagnostic kit using the same, and more particularly, to a biomarker for diagnosing peri-implantitis using an oral microbiome, a composition for diagnosing peri-implantitis using the same, and to a diagnostic kit as used.
[0008] US 8,753,820 B2 relates to diagnostic and prognostic tests for periodontal disease, utilizing a panel of biomarkers such as FAS, IL-1B, IL-8, and MMP-13, which are elevated in periodontal disease states and can be detected in gingival or saliva samples. The technology also includes methods for determining "normal" biomarker levels todiagnose periodontal disease and suggests treatments involving the inhibition of specific biomarkers like MMP-13. LPO is explicitly mentioned as marker as well.
[0009] de Aguiar MC, et al. (in: The Gingival Crevicular Fluid as a Source of Biomarkers to Enhance Efficiency of Orthodontic and Functional Treatment of Growing Patients. Biomed Res Int. 2017;2017:3257235. doi: 10.1155 / 2017 / 3257235. Epub 2017 Jan 23. PMID: 28232938; PMCID: PMC5292379) review that gingival crevicular fluid (GCF) is a biological exudate and quantification of its constituents is a current method to identify specific biomarkers with reasonable sensitivity for several biological events. Studies are being performed to evaluate whether the GCF biomarkers in growing subjects reflect both the stages of individual skeletal maturation and the local tissue remodeling triggered by orthodontic force. Present evidence is still little regarding whether and which GCF biomarkers are correlated with the growth phase (mainly pubertal growth spurt), while huge investigations have been reported on several GCF biomarkers (for inflammation, tissue damage, bone deposition and resorption, and other biological processes) in relation to the orthodontic tooth movement. In spite of these investigations, the clinical applicability of the method is still limited with further data needed to reach a full diagnostic utility of specific GCF biomarkers in orthodontics.
[0010] WO 2023 / 242373A1 discloses a method, in particular an in vitro method, for a method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant, comprising detecting, and quantifying at least one protein in a sulcus fluid sample obtained from said subject that is enriched or depleted in the sample when compared to a sulcus fluid sample obtained from a healthy implant (I) and / or a healthy tooth (T), wherein an enrichment of at least one protein as identified and / or wherein a depletion of at least one protein as identified detects a PI in said subject.
[0011] In personalized cancer precision medicine, molecular information / profiling of tumors, the microenvironment and the diseased individual is increasingly used for diagnostics and treatment decisions (Le Tourneau et al. 2019; Ahadi et al. 2020) . Mass spectrometry (MS) based proteomics enables quantification and identification of almost all proteins in the medium allowing for multibiomarker approaches and non-targeted exploratory essays (Kwon et al. 2016 ; Fretwurst 2020). In the field of periodontology, targeted proteomicmethods enabled the evaluation of approximately 100 proteins (Loos and Tjoa 2005) , when using MS based proteomics more than 600 proteins were identified in the gingival crevicular fluid of periodontitis diseased teeth (Rizal et al. 2020) . Studies demonstrated increased expressions of apolipoproteins, immunoglobulins as well as cytoskeletal proteins and histones of neutrophil extracellular traps (NETs) (Bostanci et al. 2010; Nguyen et al. 2020). MS-based proteomics of PICF has further been performed, but not including healthy implants or healthy teeth as a control group (Esberg et al. 2019), and therefore not allowing for the identification of disease specific markers or proteomic clusters. Halstenbach T, et al. (in; Impact of peri-implantitis on the proteome biology of crevicular fluid: A pilot study. J Periodontol. 2023 Jul;94(7):835-847. doi: 10.1002 / JPER.22-0461. Epub 2023 Feb 1. PMID: 36585920) present a study to reveal the proteome biology of dental implants affected with peri-implantitis. They found that diseased implants deviate strongly from healthy conditions. The PICF proteome of peri-implantitis affected sites exhibits an inflammatory fingerprint, dominated by neutrophil activity when compared with healthy implants.
[0012] There is therefore a marked interest to provide non-invasive methods for a detection of periimplantitis in contrast to healthy non-inflamed implants. It is therefore an object of the present invention to provide respective assays and methods that reliably and conveniently identify periimplantitis. Other objects and advantages will become apparent for the person of skill from studying the present description including the examples and Figures.
[0013] In a first aspect thereof, the present invention solves the above problem by providing a method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant, comprising detecting, and quantifying at least one protein marker in a sulcus fluid sample obtained from said subject that is enriched or upregulated or depleted or downregulated in the sample when compared to a sulcus fluid sample i) obtained from a healthy subject (H), ii) an earlier sulcus fluid sample taken from said subject, and / or iii) to a control sample, wherein an enrichment or upregulation of at least one protein marker selected from the group consisting of PGLYRP1, UBE2V2, and GRB2 or a depletion or downregulation of at least one protein marker selected from the group consisting of BPIFB2, LAMC2, ITGA6, and LAMA3 or a group of protein markers selected from thegroup consisting of LAMA3 in combination with at least one of BPI, GCA, GLRX, PEAK3, PRTN3, RAP1B, SHBGRL (SH3BGRL), and UBE2V2; GCA in combination with at least one of ITGA6, LAMC2, MUC7, and PAM; GLRX in combination with at least one of CST1, FCGBP, MGP, PAM, and SLPI; LAMC2 in combination with at least one of CAT, and GLRX; PAM in combination with at least one of GRB2, and RAP IB; and PGLYRP1 in combination with at least one of BPIFB2, GALNT5, LAMC2, MMP12, RPS26, and TACSTD2; CAT in combination with at least one of GRN, and GALNT5; GMFG in combination with at least one of FAT2, LAMC2, and SLPI; GRB2 in combination with at least one of ALDH3A1, ANXA8, ASS1, FAT2, FCGBP, GALNT5, GRN, PEAK3, LAMA3, LAMC2, LPO, MAL2, PAM, RPL31, RPS23, SERPINB5, SLPI, SPINT1, and TACSTD2; PEAK3 in combination with at least one of ANXA8, FAT2, LAMC2, SLPI, and TACSTD2; SHBGRL in combination with at least one of FAT2, FCGBP, MAL2, TMPRSS11B, and SPINT1; UBE2V2 in combination with at least one of ANXA8, FAT2, FCGBP, GALNT5, GRN, LAMA3, and TACSTD2; ALDH3A1 in combination with PGLYRP1, and ANXA8 in combination with GMFG detects a PI in said subject.
[0014] In the context of the present invention, samples from healthy subjects (H) preferably serve as a control. For this purpose, results of samples from subjects with healthy implants (I) and / or healthy teeth (T) may be combined. Nevertheless, in some preferred instances, the control is chosen from the groups of samples from subjects with healthy implants (I) or healthy teeth (T), as it is also explained herein.
[0015] Preferred is a method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant, comprising detecting, and quantifying at least one protein marker in a sulcus fluid sample obtained from said subject that is enriched or upregulated or depleted or downregulated in the sample when compared to a sulcus fluid sample i) obtained from a healthy subject (H), ii) an earlier sulcus fluid sample taken from said subject, and / or iii) to a control sample, wherein an enrichment or upregulation of at least one protein marker selected from the group consisting of BPI, CAT, GCA, GLRX, GRB2, PEAK3, PGLYRP1, GFMG, PRTN3, RAP1B, SH3BGRL, and UBE2V2; or wherein a depletion or downregulation of at least one protein marker selected from the group consisting ofALDH3A1, ANXA8, ASS1, FAT2, FCGBP, GALNT5, GRN, LPO, MAL2, MMP12, PAM, BPIFB2, ITGA6, LAMA3, RPS23, RPS26, SERPINB5, SLPI, SPINT1, TACSTD2, TMPRSS1 IB, and LAMC2 detects a PI in said subject.
[0016] Preferred is a method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant according to the present invention, wherein an enrichment or upregulation of at least one protein marker selected from the group consisting of CAT, GCA, GRB2, PGLYP1, PRTN3, SHBGRL, and UBE2V2 or a depletion or downregulation of at least one protein marker selected from the group consisting of BPIFB2, ITGA6, LAMA3, and LAMC2 detects a PI in said subject when compared to a sulcus fluid sample obtained from a healthy implant (I), or wherein an enrichment or upregulation of at least one protein marker selected from the group consisting of CAT, GLRX, GRB2, SHBGRL, and UBE2V2 or a depletion or downregulation of at least one protein marker selected from the group consisting of BPIFB2, ITGA6, LAMA3, LAMC2, and PAM detects a PI in said subject when compared to a sulcus fluid sample obtained from a healthy tooth (T).
[0017] In the context of the present invention, furthermore combinations were generated consisting each of two protein markers, one of which showed increased abundance and one of which showed decreased abundance in the peri-implantitis affected implants (PI) compared to the healthy implants (I) and / or healthy teeth (T), and / or a healthy sample (H).
[0018] In a second aspect thereof, the present invention solves the above problem by providing a method for diagnosing the status of peri-implantitis (PI) in a mammalian subject having a tooth implant, comprising performing the method according to the present invention, and diagnosing an exacerbated state of the PI if the at least one protein marker in the sulcus fluid sample obtained from said subject is further enriched or further depleted in the sample when compared to an earlier sulcus fluid sample obtained from the subject.
[0019] In a third aspect thereof, the present invention solves the above problem by providing a method for identifying a compound that is active against PI, comprising the steps of: a) providing at least one candidate compound with a subject suffering from PI, and b) performing the method according to the present invention, wherein a lesser enrichmentand / or a lesser depletion of at least one protein in the sulcus fluid sample in the presence of said candidate compound, when compared to the absence of said candidate compound identifies a compound that is active against PI.
[0020] In a fourth aspect thereof, the present invention solves the above problem by providing a compound that is active against PI as identified according to the present invention, or a pharmaceutical composition comprising said compound that is active against PI, together with a pharmaceutically acceptable carrier.
[0021] In a fifth aspect thereof, the present invention solves the above problem by providing a method for monitoring of a treatment or prophylaxis against PI in a mammalian subject in need thereof, comprising a) providing a treatment or prophylaxis against PI to said subject, comprising administering to said subject a compound or pharmaceutical composition that is active against PI, preferably a compound or pharmaceutical composition according to the present invention, b) performing the method according to the present invention on a biological sample obtained from said subject, and c) comparing the enrichment and / or depletion of at least one protein in the sulcus fluid sample as detected with the enrichment and / or depletion of the at least one protein in an earlier sulcus fluid sample taken from said subject, and / or to a control (H) sample.
[0022] In a sixth aspect thereof, the present invention solves the above problem by providing a method for preventing or treating PI in a mammalian subject, comprising administering to said subject an effective amount of the compound that is active against PI or the pharmaceutical composition comprising said compound that is active against PI according to the present invention.
[0023] In a seventh aspect thereof, the present invention solves the above problem by providing a compound that is active against PI or the pharmaceutical composition comprising said compound that is active against PI according to the present invention for use in the prevention or treatment of PI in a subject.
[0024] It was surprisingly found in the context of the present invention that in some instances healthy implants (I) and healthy teeth (T) exhibit a markedly different, significant andspecific sulcus protein marker signature than diseased implants with peri-implantitis (PI). Thus, proteomics enables identification of specific proteins in the peri-implant crevicular fluid (PICF), also termed herein peri-implant sulcus fluid or sulcus fluid. In the context of the present invention, the sulcus fluid is of particular interest, and in the context of the present invention "sulcus fluid" shall mean the fluid in the crevices between tooth or implant, respectively, and the gingival tissue. Sulcus has to be distinguished from sputum. Sulcus fluid is usually and preferably collected from the sulcus in a minimum depth of 1-2 mm and may be collected with sterile paper strips by insertion for about 30 sec, like, for example, gingival crevicular fluid (GCF). Preferred examples are endodontic paper points or periopapers.
[0025] In the context of the present invention, protein markers are identified. According to the invention, these markers can be any part of the underlying protein that is sufficient to specifically identify the marker. Respective assays are described herein (e.g. ELISA, etc.) and can detect the markers directly (e.g. through antibody binding, mass spectroscopy or the like) or indirectly (e.g. using expression analysis of the genes of the proteins). Preferred is the direct detection.
[0026] Nazar Majeed, Zeyad et al. (in: Identification of Gingival Crevicular Fluid Sampling, Analytical Methods, and Oral Biomarkers for the Diagnosis and Monitoring of Periodontal Diseases: A Systematic Review. Disease markers vol. 2016 (2016): 1804727. doi: 10.1155 / 2016 / 1804727) evaluate from current scientific literature the most common and precise method for gingival crevicular fluid (GCF) sample collection, biomarker analytical methods, and the variability of biomarker quantification, even when using the same analytical technique. 73.1% of the researchers analyzed their samples by using enzyme-linked immunosorbent assay (ELISA). 22.6%, 19.5%, and 18.5% of the researchers included interleukin- 1 beta (IL-lfi), matrix metalloproteinase-8 (MMP-8), and tumor necrosis factor-alpha (TNF-a), respectively, in their studies as biomarkers for periodontal disease. Paper strips are the most convenient and accurate method for gingival crevicular fluid collection, while enzyme-linked immunosorbent assay can be considered the most conventional method for the diagnosis of biofluids.In recent years, some biomarkers in the peri-implant sulcus fluid (PICF) were mainly examined using ELISA, spectrophotometry, or flow cytometry (Alassy et al. 2019). Nevertheless, using these analytical techniques only a very limited number of proteins could be detected, and the functional composition of the sulcus fluid could not be sufficiently assessed.
[0027] Pro-inflammatory cytokines, such as TNF, IL-1, IL-6, IL- 12, IL- 17, anti-inflammatory cytokines, such as IL-4 and IL- 10, biomarkers of bone metabolism, such as receptor activator nuclear factor kappa-B ligand (RANKL), receptor activator nuclear factor B (RANK), osteoprotegerine (OPG) and osteocalcin, as well as specific enzymes, such as matrix metalloproteinases (MMP1, MMP8, MMP9, MMP13) and tissue inhibitor of metalloproteinases (TIMP) were in the focus of peri-implantitis research (Alassy et al.
[0028] 2019, Iglhaut et al. 2021).
[0029] Hu Z, et al. (in: Inflammatory cytokine profiles in the crevicular fluid around clinically healthy dental implants compared to the healthy contralateral side during the early stages of implant function. Arch Oral Biol. 2019 Dec; 108: 104509. doi: 10.1016 / j. archoralbio.2019.104509. Epub 2019 Jul 29. PMID: 31494437) describe and compare cytokines levels in clinically healthy sites of dental implants and natural teeth.
[0030] Thus, research focused on only some biomarkers that were selected a priori, and so far have not been fully validated for a diagnosis.
[0031] As mentioned above, in a first aspect thereof, the present invention solves the above problem by providing a method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant, comprising detecting, and quantifying at least one protein in a sulcus fluid sample obtained from said subject that is enriched or upregulated or depleted or downregulated in the sample when compared to a sulcus fluid sample i) obtained from a healthy subject (H), ii) an earlier sulcus fluid sample taken from said subject, and / or iii) to a control sample,
[0032] wherein an enrichment or upregulation of at least one protein marker selected from the group consisting of PGLYRP1, UBE2V2, and GRB2 or a depletion or downregulation ofat least one protein marker selected from the group consisting of BPIFB2, LAMC2, ITGA6, and LAMA3 or a group of protein markers selected from the group consisting of LAMA3 in combination with at least one of BPI, GCA, GLRX, PEAK3, PRTN3, RAP1B, SHBGRL (SH3BGRL), and UBE2V2;
[0033] GCA in combination with at least one of ITGA6, LAMC2, MUC7, and PAM;
[0034] GLRX in combination with at least one of CST1, FCGBP, MGP, PAM, and SLPI; LAMC2 in combination with at least one of CAT, and GLRX;
[0035] PAM in combination with at least one of GRB2, and RAP IB; and
[0036] PGLYRP1 in combination with at least one of BPIFB2, GALNT5, LAMC2, MMP12, RPS26, and TACSTD2;
[0037] CAT in combination with at least one of GRN, and GALNT5; GMFG in combination with at least one of FAT2, LAMC2, and SLPI; GRB2 in combination with at least one of ALDH3A1, ANXA8, ASS1, FAT2, FCGBP, GALNT5, GRN, PEAK3, LAMA3, LAMC2, LPO, MAL2, PAM, RPL31, RPS23, SERPINB5, SLPI, SPINT1, and TACSTD2; PEAK3 in combination with at least one of ANXA8, FAT2, LAMC2, SLPI, and TACSTD2; SHBGRL in combination with at least one of FAT2, FCGBP, MAL2, TMPRSS1 IB, and SPINT1; UBE2V2 in combination with at least one of ANXA8, FAT2, FCGBP, GALNT5, GRN, LAMA3, and TACSTD2; ALDH3A1 in combination with PGLYRP1, and ANXA8 in combination with GMFG detects a PI in said subject.
[0038] Preferred is the method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant according to the present invention, wherein an enrichment or upregulation of at least one protein marker selected from the group consisting of BPI, CAT, GCA, GRB2, GLRX, GFMG, PEAK3, PGLYP1, PRTN3, RAP1B, SHBGRL (SH3BGRL), and UBE2V2 or a depletion or downregulation of at least one protein marker selected from the group consisting of ALDH3A1, ANXA8, ASS1, FAT2, FCGBP, GALNT5, GRN, LPO, MAL2, MMP12, PAM, BPIFB2, ITGA6, LAMA3, RPS23, RPS26, SERPINB5, SLPI, SPINT1, TACSTD2, TMPRSS1 IB, and LAMC2 detects a PI in said subject when compared to a sulcus fluid sample obtained from a healthy implant (I), or
[0039] wherein an enrichment or upregulation of at least one protein marker selected from the group consisting of CAT, GLRX, GRB2, SHBGRL, and UBE2V2 or a depletion or downregulation of at least one protein marker selected from the group consisting ofBPIFB2, ITGA6, LAMA3, LAMC2, and PAM detects a PI in said subject when compared to a sulcus fluid sample obtained from a healthy tooth (T).
[0040] As mentioned above, in the context of the present invention, protein markers were identified that each are significant with a moderated or adjusted p-value of< 0.05 and / or a significance of an AUC >0.80 for a distinction between PI and healthy samples (H) or healthy implants (I). Furthermore, combinations were generated, consisting each of two proteins / markers, one of which showed increased abundance and one of which showed decreased abundance in the peri-implantitis affected implants (PI) compared to the healthy samples (H) or healthy implants (I). These combinations represent particularly preferred marker panels and / or can be combined as desired in the assays as performed in the context of the present invention.
[0041] Upregulated protein markers in PI as identified were BPI, CAT, GCA, GLRX, GRB2, PEAK3, PGLYRP1, PRTN3, RAP1B, SH3BGRL, and UBE2V2. Downregulated protein markers in PI as identified were BPIFB2, CST1, FCGBP, ITGA6, LAMA3, LAMC2, MGP MUC7, PAM, and SLPI.
[0042] Therefore, preferred combinations of proteins / markers are selected from the group consisting of BPI and LAMA3; CAT and LAMC2; GCA and ITGA6; GCA and LAMA3; GCA and LAMC2; GCA and MUC7; GCA and PAM; GLRX and CST1; GLRX and FCGBP; GLRX and LAMA3; GLRX and LAMC2; GLRX and MGP; GLRX and PAM; GLRX and SLPI; GRB2 and PAM; PEAK3 and LAMA3; PGLYRP1 and BPIFB2; PRTN3 and LAMA2; RAP1B and LAMA3; RAP1B and PAM; SH3BGRL and LAMA3; and UBE2V2 and LAMA3.
[0043] Further upregulated protein markers in PI as identified were CAT, GLRX, GMFG, GRB2, PEAK3, PGLYRP1, SHBGRL, and UBE2V2. Downregulated protein markers in PI as identified were ALDH3A1, ANXA8, ASS1, FAT2, FCGBP, GALNT5, GRN, LAMA3, LAMC2, LPO, MAL2, MMP12, PAM, RPL31, RPS23, RPS26, SERPINB5, SLPI, SPINT1, TACSTD2, and TMPRSS11B.Therefore, further preferred combinations of proteins / markers are selected from the group consisting of CAT and GRN, CAT and GALNT5, CAT and LAMC2, GLRX and LAMC2, GLRX and SLPI, GMFG and FAT2, GMFG and LAMC2, GMFG and SLPI, GRB2 and ALDH3A1, GRB2 and ANXA8, GRB2 and ASS1, GRB2 and FAT2, GRB2 and FCGBP, GRB2 and GALNT5, GRB2 and GRN, GRB2 and PEAK3, GRB2 and LAMA3, GRB2 and LAMC2, GRB2 and LPO, GRB2 and MAL2, GRB2 and PAM, GRB2 and RPL31, GRB2 and RPS23, GRB2 and SERPINB5, GRB2 and SLPI, GRB2 and SPINT1, GRB2 and TACSTD2, PEAK3 and ANXA8, PEAK3 and FAT2, PEAK3 and LAMC2, PEAK3 and SLPI, PEAK3 and TACSTD2, PGLYRP1 and GALNT5, PGLYRP1 andLAMC2, PGLYRP1 andMMP12, PGLYRP1 andRPS26, PGLYRP1 and TACSTD2, SHBGRL and FAT2, SHBGRL and FCGBP, SHBGRL and MAL2, SHBGRL and TMPRSS11B, SHBGRL and SPINT1, UBE2V2 and ANXA8, UBE2V2 and FAT2, UBE2V2 and FCGBP, UBE2V2 and GALNT5, UBE2V2 and GRN, UBE2V2 and LAMA3, UBE2V2 and TACSTD2, ALDH3A1 and PGLYRP1, and ANXA8 and GMFG
[0044] With a lack of specific detection and diagnostic tools for peri-implantitis and only minor understanding of underlying molecular biology, diagnostics, therapy, and prognostics of peri-implant diseases pose a challenge to clinicians (Ramanauskaite et al. 2021) . The present invention thus assessed the proteomic composition of PICF of peri-implantitis affected implants in comparison to healthy implants and teeth in an untargeted approach to reveal the proteomic difference between healthy and diseased implants. Furthermore, included is a method that detects PI based on the changes when compared to an earlier sulcus fluid sample taken from said subject, i.e. based on the "internal" comparison of markers.
[0045] In the context of the present invention, peri-implantitis (PI) is defined according to the current international guideline with peri-implant pocket depth > 6 mm, > 3 mm periimplant radiological bone loss with bleeding and / or suppuration on probing (Berglundh 2018).
[0046] As mentioned above, it was surprisingly found in the context of the present invention that healthy implants and teeth (H) exhibit a significantly different and specific sulcus proteinmarker signature than diseased implants with peri-implantitis (PI). Therefore, preferred is the method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant according to the present invention, wherein the significance of the at least one protein marker has a moderated p-value of < 0.05, more preferably of < 0.01 and / or a significance of an AUC >0.80. Further preferred is the method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant according to the present invention, wherein the significance of the combination of the protein markers as analyzed has a moderated p-value of < 0.05, more preferably of < 0.01, and most preferred of less than 0.005 and / or a significance of an AUC >0.80, preferably >0.90.
[0047] Sulcus fluid is usually and preferably collected from the sulcus in a minimum depth of 1-2 mm and may be collected with sterile paper strips by insertion for about 30 sec, like, for example, gingival crevicular fluid (GCF). Preferred examples are endodontic paper points or periopapers. Preferred is the method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant according to the present invention, wherein the sulcus fluid sample was obtained from said subject using sterile paper strips such as, for example, are endodontic paper points or periopapers.
[0048] In general, the detection and quantification of the at least one protein marker in the sample can be performed by any suitable method as is known to the person of skill. Preferred is the method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant according to the present invention, wherein the detection and quantification of the at least one protein in the sample comprises a method selected from at least one of Enzyme-linked Immunosorbent Assay (ELISA), endogenous proteolytic activity assay, bicinchoninic acid assay, and mass spectrometry. These methods and assays are disclosed herein and known to the person of skill.
[0049] The present method may be performed with a sample from any mammal having a tooth implant, suspected of suffering from PI. Preferred is the method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant according to the present invention, wherein the mammalian subject is selected from a cat, dog, mouse, rat, horse, sheep, goat, monkey, cow, or human. Preferred is a human.Another aspect of the present invention then relates to a method for diagnosing the status of peri-implantitis (PI) in a mammalian subject having a tooth implant, comprising performing the method according to the present invention, and diagnosing an exacerbated state of the PI if the at least one protein in the sulcus fluid sample obtained from said subject is further enriched or further depleted in the sample when compared to an earlier sulcus fluid sample obtained from the subject.
[0050] In another aspect of the present invention, the present invention can be used to improve the prevention and treatment of a PI in a subject. The present invention provides a method for identifying a compound that is active against PI, comprising the steps of: a) providing at least one candidate compound with a subject suffering from PI, and b) performing the method according to the present invention, wherein a lesser enrichment and / or a lesser depletion of at least one protein in the sulcus fluid sample in the presence of said candidate compound, when compared to the absence of said candidate compound identifies a compound that is active against PI.
[0051] In principle, any suitable candidate compound may be screened. Preferred is the method for identifying a compound that is active against PI according to the present invention, wherein the candidate compound is selected from the group consisting of a chemical molecule, a molecule selected from a library of small organic molecules (molecular weight less than 500 Da), a molecule selected from a combinatory library, a cell extract, in particular a plant cell extract, a small molecular drug, a protein, a protein fragment, a molecule selected from a peptide library, and an antibody or fragment thereof. Methods for screening are known in the art, preferred is a high-throughput method (HTS). Preferred is a screening in a suitable animal model. These candidate molecules may also be used as a basis to screen for improved compounds. Thus, preferred is the method according to the present invention, wherein after the identification of the anti-PI compound, the method further comprises the step of chemically modifying the compound. In general, many methods of how to modify compounds of the present invention are known to the person of skill and are disclosed in the literature. Modifications of the compounds will usually fall into several categories, for example a) mutations / changes of amino acids into different amino acids, b) chemical modifications, e.g., through the addition of additional chemical groups, c) changes of the size / length ofthe compound, and / or d) the attachment of additional groups to the molecule (including marker groups, labels, linkers or carriers, such as chelators). In a next step, the modified compound is tested again in at least one of tests as above, and if the property of the compound is improved compared to its unaltered state.
[0052] Yet another aspect of the present invention then relates to a compound that is active against PI as identified according to a method according to the present invention, or a pharmaceutical composition comprising said compound that is active against PI, together with a pharmaceutically acceptable carrier. Preferred is a compound that is active against PI according to the present invention, wherein the compound is selected from the group consisting of a chemical molecule, a molecule selected from a library of small organic molecules, a molecule selected from a combinatory library, a cell extract, in particular a plant cell extract, a small molecular drug, a protein, a protein fragment, a molecule selected from a peptide library, and an antibody or fragment thereof.
[0053] Pharmaceutical compositions as used may optionally comprise a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers or excipients include diluents (fillers, bulking agents, e.g. lactose, microcrystalline cellulose), disintegrants (e.g. sodium starch glycolate, croscarmellose sodium), binders (e.g. PVP, HPMC), lubricants (e.g. magnesium stearate), glidants (e.g. colloidal SiCh), solvents / co-solvents (e.g. aqueous vehicle, propylene glycol, glycerol), buffering agents (e.g. citrates, gluconates, lactates), preservatives (e.g. Na benzoate, parabens (Me, Pr and Bu), BKC), anti -oxidants (e.g. BHT, BHA, Ascorbic acid), wetting agents (e.g. polysorbates, sorbitan esters), thickening agents (e.g. methylcellulose or hydroxyethylcellulose), sweetening agents (e.g. sorbitol, saccharin, aspartame, acesulfame), flavoring agents (e.g. peppermint, lemon oils, butterscotch, etc.), humectants (e.g. propylene, glycol, glycerol, sorbitol). Other suitable pharmaceutically acceptable excipients are inter alia described in Remington's Pharmaceutical Sciences, 15th Ed., Mack Publishing Co., New Jersey (1991) and Bauer et al, Pharmazeutische Technologic, 5th Ed., Govi-Verlag Frankfurt (1997). The person skilled in the art knows suitable formulations for the compounds as described herein and will readily be able to choose suitable pharmaceutically acceptable carriers or excipients, depending, e.g., on the formulation and administration route of the pharmaceutical composition.The pharmaceutical composition can be administered orally, e.g., in the form of pills, tablets, coated tablets, sugar coated tablets, hard and soft gelatin capsules, solutions, syrups, emulsions or suspensions, or as aerosol mixtures. Administration, however, can also be carried out rectally, e.g., in the form of suppositories, or parenterally, e.g., in the form of injections or infusions, or percutaneously, e.g., in the form of ointments, creams or tinctures.
[0054] In addition to the aforementioned compounds of the invention, the pharmaceutical composition can contain further customary, usually inert carrier materials or excipients. Thus, the pharmaceutical preparations can also contain additives, such as, for example, fillers, extenders, disintegrants, binders, glidants, wetting agents, stabilizers, emulsifiers, preservatives, sweetening agents, colorants, flavorings or aromatizers, buffer substances, and furthermore solvents or solubilizers or agents for achieving a depot effect, as well as salts for changing the osmotic pressure, coating agents or antioxidants. They can also contain the aforementioned salts of two or more compounds as identified according to the invention and also other therapeutically active substances as described herein.
[0055] Another aspect of the present invention relates to a method for producing a pharmaceutical composition comprising formulating at least one anti-PI compound as identified herein with a pharmaceutically acceptable carrier.
[0056] Yet another aspect of the present invention then relates to a method, such as diagnostic method, for monitoring of a treatment or prophylaxis against PI in a mammalian subject in need thereof, comprising a) providing a treatment or prophylaxis against PI to said subject, comprising administering to said subject a compound or pharmaceutical composition that is active against PI, preferably a compound or pharmaceutical composition according to the present invention, b) performing the method according to the present invention on a biological sample obtained from said subject, and c) comparing the enrichment and / or depletion of at least one protein in the sulcus fluid sample as detected with the enrichment and / or depletion of the at least one protein in an earlier sulcus fluid sample taken from said subject, and / or to a control sample (H). Preferred is the method, wherein a decrease of the enriched protein and / or an increase of the depletedprotein is indicative for the success of, progress of and / or sensitivity for the anti-IP treatment or prophylaxis in the mammalian subject. The method may further comprise adjusting the treatment or prophylaxis of said subject or patient based on said monitoring. The attending physician will be readily able to make and apply respective treatment decisions, also taking into account additional patient parameters, if required.
[0057] Yet another aspect of the present invention then relates to a method for preventing or treating PI in a mammalian subject, comprising administering to said subject an effective amount of the compound that is active against PI or the pharmaceutical composition comprising said compound that is active against PI according to the present invention.
[0058] Preferred is the method according to the present invention, wherein the anti-PI treatment or prophylaxis in the patient or subject comprises administering an effective amount of the compound as identified herein in a pharmaceutical composition as described.
[0059] As mentioned herein, the compound is administered to said subject in an effective dosage. This dosage can vary within wide limits and is to be suited to the individual conditions in each individual case. For the above uses, the appropriate dosage will vary depending on the mode of administration, the particular condition to be treated and the effect desired. In general, however, satisfactory results are achieved at dosage rates are as above, e.g. of about 1 to 100 mg / kg animal body weight particularly 1 to 50 mg / kg. Suitable dosage rates for larger mammals, for example humans, are of the order of from about 10 mg to 3 g / day, conveniently administered once or in divided doses, e.g. 2 to 4 times a day, or in sustained release form. In general, a daily dose of approximately 10 mg to 100 mg, particularly 10 to 50 mg, per human individual is appropriate in the case of the oral administration. An effective concentration to be reached at the cellular level can be set at between 50 to 200 pM, preferably at about 100 pM. Particularly preferred is topical application, such as to the airways by inhalation. In these cases, the dosage can be conveniently reduced to between 0.1 to 10 mg / dose, preferably 0.2 to 5 mg per dose, which equals about 3 to about 80 pg per kilogram for a 70 kg subject.
[0060] It is to be understood that the present compound and / or a pharmaceutical composition comprising the present compound is for use to be administered to a human patient. Theterm "administering" means administration of a sole therapeutic agent or in combination with another therapeutic agent. It is thus envisaged that the pharmaceutical composition of the present invention is employed in co-therapy approaches, i.e. in co-administration with other medicaments or drugs and / or any other therapeutic agent which might be beneficial in the context of the methods of the present invention. Nevertheless, the other medicaments or drugs and / or any other therapeutic agent can be administered separately from the compound for use, if required, as long as they act in combination (i.e. directly and / or indirectly, preferably synergistically) with the present compound for use.
[0061] Thus, the compounds of the invention can be used alone or in combination with other active compounds - for example with medicaments already known for the prevention or treatment of PI, whereby in the latter case a favorable additive, amplifying or preferably synergistically effect is noticed. Suitable amounts to be administered to humans range from 1 to 500 mg, in particular 5 mg to 100 mg, such as between 1 and 10 mg / kg / day oral dose. An effective concentration to be reached at the cellular level can be set at between 50 to 200 pM, preferably at about 100 pM.
[0062] In the medical use aspects of the present invention, the compound (for use) can be provided and / or is administered as a suitable pharmaceutical composition, such as a tablet, capsule, injection, granule, powder, sachet, reconstitutable powder, dry powder inhaler, inhalation, and / or chewable. Such solid formulations may comprise excipients and other ingredients in suitable amounts. Such solid formulations may contain e.g., cellulose, cellulose microcrystalline, polyvidone, in particular FB polyvidone, magnesium stearate and the like. Administration, however, can also be carried out rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injections or infusions, or percutaneously, e.g. in the form of ointments, creams or tinctures.
[0063] Preferred is the use of the (local) inhibition of proteases as identified in the sulcus; further preferred examples include the injection of inhibitor depots.
[0064] The compound that is active against PI or the pharmaceutical composition comprising said compound that is active against PI according to the present invention is also for use in the prevention or treatment of PI in a subject as above.Yet another aspect of the present invention then relates to a diagnostic or therapeutic kit comprising materials for performing a method according to the present invention in one or separate containers, optionally together with auxiliary agents and / or instructions for performing said method.
[0065] Preferred is a diagnostic or therapeutic kit according to the present invention comprising at least one of a specific antibody binding to the at least protein as above, dyes and other labels, as well as buffers and matrices for performing the methods as above. The kit may further comprise manuals, paper strips, proteases, and other materials for mass spectrometry analysis as herein.
[0066] The kit may be used in the methods of the invention, i.e., for identifying an anti-PI compound, for detecting PI in a mammalian subject, for monitoring an anti-PI treatment or prophylaxis in a patient or subject in need thereof, and / or for an anti-PI treatment or prophylaxis in a patient or subject.
[0067] The following uses are derived from the present invention:
[0068] Peri-implantitis (PI) can be detected in a non-invasive, biochemical way by detecting and quantifying the inventive sulcus protein markers (alone or in combination).
[0069] The present invention forms the basis for the translational application and further development of the inventors' findings in order to enable longitudinal, multi-modal monitoring of peri-implant diseases in the near future and, based on this, to pursue personalized prevention and therapy concepts (Steinhubl 2019, Schiissler -Fiorenza Rose 2019).
[0070] With a lack of specific diagnostic tools for peri-implantitis and only minor understanding of underlying molecular biology, diagnostics, therapy, and prognostics of peri-implant diseases pose a challenge to clinicians (Ramanauskaite et al. 2021). The present invention helps to overcome this problem.According to the present invention, peri-implantitis-diseased implants can be detected in a non-invasive, biochemical way by means of detection and quantification of said protein marker combinations from the sulcus fluid of peri-implantitis-diseased implants in comparison to healthy implants or healthy teeth.
[0071] The present invention relates to the following items.
[0072] Item 1. A method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant, comprising detecting, and quantifying at least one protein marker in a sulcus fluid sample obtained from said subject that is enriched or upregulated or depleted or downregulated in the sample when compared to a sulcus fluid sample i) obtained from a healthy subject (H), ii) an earlier sulcus fluid sample taken from said subject, and / or iii) to a control sample, wherein an enrichment or upregulation of at least one protein marker selected from the group consisting of PGLYRP1, UBE2V2, and GRB2, or a depletion or downregulation of at least one protein marker selected from the group consisting of BPIFB2, LAMC2, ITGA6, and LAMA3, or a group of protein markers selected from the group consisting of LAMA3 in combination with at least one of BPI, GCA, GLRX, PEAK3, PRTN3, RAP1B, SHBGRL (SH3BGRL), and UBE2V2; GCA in combination with at least one of ITGA6, LAMC2, MUC7, and PAM; GLRX in combination with at least one of CST1, FCGBP, MGP, PAM, and SLPI; LAMC2 in combination with at least one of CAT, and GLRX; PAM in combination with at least one of GRB2, and RAP IB; and PGLYRP1 in combination with at least one of BPIFB2, GALNT5, LAMC2, MMP12, RPS26, and TACSTD2; CAT in combination with at least one of GRN, and GALNT5; GMFG in combination with at least one of FAT2, LAMC2, and SLPI; GRB2 in combination with at least one of ALDH3A1, ANXA8, ASS1, FAT2, FCGBP, GALNT5, GRN, PEAK3, LAMA3, LAMC2, LPO, MAL2, PAM, RPL31, RPS23, SERPINB5, SLPI, SPINT1, and TACSTD2; PEAK3 in combination with at least one of ANXA8, FAT2, LAMC2, SLPI, and TACSTD2; SHBGRL in combination with at least one of FAT2, FCGBP, MAL2, TMPRSS11B, and SPINT1; UBE2V2 in combination with at least one of ANXA8, FAT2, FCGBP, GALNT5, GRN, LAMA3, and TACSTD2; ALDH3A1 in combination with PGLYRP1, and ANXA8 in combination with GMFG detects a PI in said subject..Item 2. Method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant according to Item 1, wherein an enrichment or upregulation of at least one protein marker selected from the group consisting of BPI, CAT, GCA, GRB2, GLRX, GFMG, PEAK3, PGLYP1, PRTN3, RAP1B, SHBGRL (SH3BGRL), and UBE2V2 or a depletion or downregulation of at least one protein marker selected from the group consisting of ALDH3A1, ANXA8, ASS1, FAT2, FCGBP, GALNT5, GRN, LPO, MAL2, MMP12, PAM, BPIFB2, ITGA6, LAMA3, RPS23, RPS26, SERPINB5, SLPI, SPINT1, TACSTD2, TMPRSS1 IB, and LAMC2 detects a PI in said subject when compared to a sulcus fluid sample obtained from a healthy implant (I), or wherein an enrichment or upregulation of at least one protein marker selected from the group consisting of CAT, GLRX, GRB2, SHBGRL, and UBE2V2 or a depletion or downregulation of at least one protein marker selected from the group consisting of BPIFB2, ITGA6, LAMA3, LAMC2, and PAM detects a PI in said subject when compared to a sulcus fluid sample obtained from a healthy tooth (T).
[0073] Item 3. Method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant according to Item 1 or 2, wherein the significance of the at least one protein marker has a moderated or adjusted p-value of< 0.05, and / or a significance of an AUC >0.80.
[0074] Item 4. Method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant according to any one of Items 1 to 3, wherein the sulcus fluid sample was obtained from said subject using sterile paper strips such as, for example, are endodontic paper points or periopapers.
[0075] Item 5. The method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant according to any one of Items 1 to 4, wherein the detection and quantification of the at least one protein in the sample comprises a method selected from at least one of ELISA, bicinchoninic acid assay, and mass spectrometry.
[0076] Item 6. The method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant according to any one of Items 1 to 5, further comprising detecting endogenous proteolysis in the sample, wherein a higher endogenous proteolytic activityas detected when compared to a non-PI sample, an I sample, a T sample, and / or a control H sample indicates a PI sample, wherein preferably detecting a higher endogenous proteolytic activity comprises detecting of proportional intensities of semi-specific peptides.
[0077] Item 7. The method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant according to any one of Items 1 to 6, wherein the mammalian subject is selected from a cat, dog, mouse, rat, horse, sheep, goat, monkey, cow, or human, preferably a human.
[0078] Item 8. A method for diagnosing the status of peri-implantitis (PI) in a mammalian subject having a tooth implant, comprising performing the method according to any one of Items 1 to 7, and diagnosing an exacerbated state of the PI if the at least one protein in the sulcus fluid sample obtained from said subject is further enriched or further depleted in the sample when compared to an earlier sulcus fluid sample obtained from the subject.
[0079] Item 9. A method for identifying a compound that is active against PI, comprising the steps of: a) providing at least one candidate compound with a subject suffering from PI, and b) performing the method according to any one of Items 1 to 7, wherein a lower enrichment and / or a lower depletion of at least one protein in the sulcus fluid sample in the presence of said candidate compound, when compared to the absence of said candidate compound, identifies a compound that is active against PI.
[0080] Item 10. The method for identifying a compound that is active against PI according to Item 9, wherein the candidate compound is selected from the group consisting of a chemical molecule, a molecule selected from a library of small organic molecules, a molecule selected from a combinatory library, a cell extract, in particular a plant cell extract, a small molecular drug, a protein, a protein fragment, a molecule selected from a peptide library, and an antibody or fragment thereof.
[0081] Item 11. A compound that is active against PI as identified according to a method according to Item 9 or 10, or a pharmaceutical composition comprising said compound that is active against PI, together with a pharmaceutically acceptable carrier.Item 12. A method for monitoring of a treatment or prophylaxis against PI in a mammalian subject in need thereof, comprising a) providing a treatment or prophylaxis against PI to said subject, comprising administering to said subject a compound or pharmaceutical composition that is active against PI, preferably a compound or pharmaceutical composition according to Item 11, b) performing the method according to any one of Items 1 to 7 on a biological sample obtained from said subject, and c) comparing the enrichment and / or depletion of at least one protein in the sulcus fluid sample as detected with the enrichment and / or depletion of the at least one protein in an earlier sulcus fluid sample taken from said subject, and / or to a control (H) sample.
[0082] Item 13. The compound that is active against PI or the pharmaceutical composition comprising said compound that is active against PI according to Item 11 for use in the prevention or treatment of PI in a subject.
[0083] Item 14. A diagnostic or therapeutic kit comprising materials for performing a method according to any one of Items 1 to 10 or 12 in one or separate containers, optionally together with auxiliary agents, a compound that is active against PI as identified according to a method according to Item 9 or 10, and / or instructions for performing said method.
[0084] Item 15. Use of the diagnostic or therapeutic kit according to item 14 for monitoring of a treatment or prophylaxis against PI in a mammalian subject in need thereof, in the prevention or treatment of PI in a subj ect, for identifying a compound that is active against PI, and / or for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant according to the present invention.
[0085] The invention will now be further described in the following examples and with reference to the accompanying figures, without being limited thereto. For the purposes of the present invention, all references as cited herein are incorporated by reference in their entireties.
[0086] Figure 1 shows a differential abundance analysis of the discovery cohort and the selection of the 21 protein markers based on the analysis.Figure 2 shows classification models for differentiating between implants affected by peri-implantitis and healthy implants in the discovery cohort and the validation cohort.
[0087] Figure 3 shows classification models that differentiate between peri-implantitis affected and healthy implants (I) based on 2-protein combinations and with an AUC value > 0.80 in detection and validation cohorts.
[0088] Figure 4 shows boxplots of the Log2 intensities in the discovery cohort of the 21 proteins within the 242-protein combinations. Asterisks indicate the results of the Wilcoxon rank sum test with * for p-value< 0.05, ** for p-value< 0.01, *** for p-value< 0.001 and **** for p-value < 0.0001. IK.
[0089] Figure 5 shows boxplots of the Log2 delta of the intensities in the discovery cohort of the 21 proteins for healthy implant (I) (light gray) vs. peri-implantitis (PI) (dark gray).
[0090] Figure 6 shows additional classification models that differentiate between peri-implantitis affected (PI) and healthy implants (I) based on 2-protein combinations and with an AUC value > 0.80 in detection and validation cohorts. A) Fold changes (FCs) in abundance of the 29 proteins across the 51 panels shown in B). B) ROC plots of the 51 two-protein panels with AUC > 0.90 in both cohorts, PI and I. C) Validation of three preferred panels using XGBoost classification models.
[0091] EXAMPLES
[0092] Within a large-scale study, two independent cohorts (discovery cohort and validation cohort) of sulcus fluid samples were analyzed using mass spectrometry -based proteomics. In the discovery cohort 100 sulcular fluid samples from 37 patients and in the validation cohort 113 sulcular fluid samples from 40 patients were analyzed. The sulcular fluid samples were divided into three sample types: 1. peri-implantitis-affected implants (PI), 2. healthy implants (I) and 3. healthy teeth (T).The proteome profiles of both cohorts were analyzed in a differential abundance analysis (Fig. 1). In the discovery cohort, 917 proteins were identified whose abundances differed significantly (p-value < 0.05) in the three sample types. In the validation cohort, 1837 such proteins were identified. A comparison of these proteins from both cohorts resulted in an intersection of 80 proteins, each of which showed significantly different abundances in both cohorts and also differed quantitatively by > 75 % (corresponding to a |Log2 ratio| > 0.8) in the peri-implantitis-diseased implants and healthy implants.
[0093] Machine learning was used to train classification models that learned to distinguish between peri-implantitis affected and healthy implants based on the proteomic data of the selected 80 proteins. Independent models were trained for both cohorts to validate the suitability and robustness of the 80 proteins (Fig. 2). The resulting models yielded a sensitivity of 1.00, a specificity of 0.79 and an AUC (area under the receiver operating characteristics curve) value of 0.91 for the discovery cohort and a sensitivity of 0.89, a specificity of 1.00 and an AUC value of 0.97 for the validation cohort. This confirmed the selection of 80 proteins to differentiate between implants affected by peri-implantitis and healthy implants.
[0094] Example 1
[0095] Based on the validated selection of 80 proteins, combinations were generated each consisting of two proteins, one of which showed increased abundance and one of which showed decreased abundance in the peri-implantitis affected implants compared to the healthy implants (I). These combinations were used to re-train classification models based only on the proteomic data of the 2 proteins within the combination. The models were again trained independently for both cohorts to confirm the robustness of the combinations. Furthermore, a calculation of the intensity differences within each combination was performed as follows: A Log2 intensity (protein up - protein down) was determined, then the overlap of combinations where the A value differs the most between peri-implantitis vs. healthy implant in both cohorts was used. 22 combinations were identified as diagnostic panels based on the following criteria: (1) Classification models with an AUC value > 0.80 in both cohorts (Fig. 3), and (2) high difference in A Log2 intensity in both cohorts (Fig. 5).The 22 combinations consisted of a total of 21 proteins, of which 11 proteins showed increased abundance, and 10 proteins showed decreased abundance in the samples of the peri-implantitis affected implants, compared to the healthy implants. A Wilcoxon rank sum test was performed for each of these 21 proteins to confirm the significance of the quantitative difference between the peri-implantitis-affected and healthy implants and between the peri-implantitis-affected implants and the healthy teeth. A significant p-value < 0.05 was calculated for each of the 21 proteins tested when comparing peri-implantitis-affected and healthy implants (Fig. 4). In the comparison of implants affected by peri-implantitis and healthy teeth, a significant p-value < 0.05 was calculated for 21 proteins. This showed that, in addition to samples from healthy implants (I), samples from healthy teeth (T) can also be used as reference samples (controls) to differentiate between implants affected by peri-implantitis.
[0096] The most significant markers for peri-implantitis vs. healthy implant (I) were:
[0097] Upregulated marker: PGLYRP1, and GRB2
[0098] Downregulated marker: BPIFB2, and LAMA3
[0099] The most significant markers for peri-implantitis vs. healthy teeth (T) were:
[0100] Upregulated marker: UBE2V2, and GRB2
[0101] Downregulated marker: LAMC2, and ITGA6
[0102] Table 1: Preferred enriched or upregulated sulcus-protein markers or depleted or downregulated sulcus-protein markers in peri-implantitis as identified in the context of the present invention
[0103] Uniprot
[0104] Discovery Cohort Validation Cohort
[0105] IDs Genes
[0106] (Database
[0107] Log2 fold Adj. p- Log2 fold Adj. p- Status
[0108] change value change value 04 / 2025)
[0109] enriched or upregulated markers
[0110] P17213 BPI 0.89 2.51E-02 1.11 1.29E-04 P04040 CAT 1.06 2.59E-04 1.01 1.12E-04
[0111]
[0112] P28676 GCA 1.56 1.66E-03 1.77 1.14E-05 P35754 GLRX 0.93 3.71E-03 1.52 6.80E-05 P62993 GRB2 0.84 8.14E-04 1.12 9.24E-07 Q6ZS72 PEAK3 0.83 5.20E-03 0.80 1.01E-02 075594 PGLYRP1 1.24 1.48E-03 1.86 1.15E-06 P24158 PRTN3 1.13 1.82E-03 0.98 9.51E-03 P61224 RAP1B 1.09 6.71E-03 0.90 1.85E-04 075368 SH3BGRL 0.94 1.17E-03 0.93 7.32E-05 Q15819 UBE2V2 0.97 1.30E-04 0.96 5.86E-08 depleted or downregulated markers
[0113] Q8N4F0 BPIFB2 -2.64 1.76E-05 -1.44 1.57E-02 P01037 CST1 -2.40 2.99E-03 -1.41 2.15E-02 Q9Y6R7 FCGBP -1.19 4.05E-03 -0.83 4.05E-02 P23229 ITGA6 -1.19 4.71E-04 -1.07 3.86E-05 Q16787 LAMA3 -1.53 2.31E-04 -1.51 3.83E-05 Q13753 LAMC2 -1.27 2.33E-05 -1.25 6.69E-04 P08493 MGP -1.71 2.48E-03 -2.04 6.77E-04 Q8TAX7 MUC7 -1.74 1.43E-02 -1.81 2.87E-03 P19021 PAM -1.48 2.62E-03 -1.20 4.35E-04 P03973 SLPI -1.26 1.01E-02 -1.74 9.88E-04
[0114]
[0115] Table 2: Names of marker genes as identified
[0116] Genes Name; Notes
[0117] BPI Bactericidal permeability-increasing protein
[0118] BPIFB2 BPI fold-containing family B member 2
[0119] CST1 Cystatin-SN
[0120] CAT Catalase
[0121] FCGBP IgGFc-binding protein
[0122] GCA Grancalcin
[0123] GLRX Glutaredoxin-1
[0124] GRB2 Growth factor receptor-bound protein 2
[0125] ITGA6 Integrin alpha-6
[0126]
[0127] LAMA3 Laminin subunit alpha-3
[0128] LAMC2 Laminin subunit gamma-2
[0129] MGP Matrix Gia protein
[0130] MUC7 Mucin-7
[0131] PAM Peptidyl-glycine alpha-amidating monooxygenase
[0132] PEAK3 Protein PEAK3
[0133] PGLYRP1 Peptidoglycan recognition protein 1
[0134] PRTN3 Myeloblastin
[0135] RAP1B Ras-related protein Rap- lb
[0136] SLPI Antileukoproteinase
[0137] SH3BGRL Adapter SH3BGRL (also abbreviated as SHBGRL)
[0138] UBE2V2 Ubiquitin-conjugating enzyme E2 variant 2
[0139]
[0140] Table 3: Preferred combinations of marker genes as identified
[0141] Discovery Cohort Validation Cohort Log2 Log2
[0142] fold fold
[0143] Protei Protein Gene
[0144] Gene up change Classificati change Classificati n up down down in on model in on model Delta(U AUC Delta(U AUC P- P- Down) Down)
[0145] P1721 LAMA
[0146] Q16787 BPI 3.35 0.81 3.87 0.86 3 3
[0147] P0404 LAMC
[0148] Q13753 CAT 3.21 0.91 3.43 0.9 0 2
[0149] P2867
[0150] P19021 GCA PAM 4.09 0.88 4.15 0.82 6
[0151] P2867 LAMA
[0152] Q16787 GCA 3.86 0.87 4.5 0.85 6 3
[0153] P2867 LAMC
[0154] Q13753 GCA 3.55 0.87 3.68 0.91 6 2
[0155] P2867 Q8TAX
[0156] GCA MUC7 3.42 0.84 3.97 0.8
[0157] 6 7
[0158] P2867
[0159] P23229 GCA ITGA6 3.19 0.81 3.66 0.83 6
[0160] P3575
[0161] P19021 GLRX PAM 3.53 0.89 4.32 0.81 4
[0162] P3575 LAMC
[0163] Q13753 GLRX 3.54 0.87 3.71 0.96
[0164]
[0165] 4 2P3575 LAMA
[0166] Q16787 GLRX 3.81 0.86 4.72 0.87
[0167] 4 3
[0168] P3575
[0169] P01037 GLRX CST1 3.58 0.85 3.77 0.8
[0170] 4
[0171] P3575
[0172] P03973 GLRX SLPI 3.3 0.85 3.45 0.9
[0173] 4
[0174] P3575
[0175] P08493 GLRX MGP 3.56 0.84 4.06 0.8
[0176] 4
[0177] P3575 Q9Y6R FCGB
[0178] GLRX 3.48 0.83 3.53 0.86
[0179] 4 7 P
[0180] P6299
[0181] P19021 GRB2 PAM 3.34 0.93 3.49 0.9
[0182] 3
[0183] Q6ZS7 LAMA
[0184] Q16787 PEAK3 3.67 0.89 3.43 0.8
[0185] 2 3
[0186] 07559 Q8N4F PGLYRP BPIFB
[0187] 3.41 0.9 3.34 0.87
[0188] 4 0 1 2
[0189] P2415 LAMA
[0190] Q16787 PRTN3 3.25 0.85 3.62 0.83
[0191] 8 3
[0192] P6122 LAMA
[0193] Q16787 RAP1B 3.69 0.87 3.88 0.93
[0194] 4 3
[0195] P6122
[0196] P19021 RAP1B PAM 4.22 0.85 3.4 0.83
[0197] 4
[0198] 07536 SH3BGR LAMA
[0199] Q16787 3.18 0.87 3.79 0.91
[0200] 8 L 3
[0201] Q1581 LAMA
[0202] Q16787 UBE2V2 3.24 0.91 3.8 0.92
[0203] 9 3
[0204] Example 2
[0205] In a second set of analyses, from the pool of 80 biomarker candidates, the inventors compiled a list of all two-protein panels containing one protein upregulated and one downregulated in peri-implantitis, to facilitate future translation into point-of-care tests. These 975 panels were used for classification model construction in each cohort. 51 two-protein panels yielded ROC AUC values > 0.90 in both cohorts, i.e., each of these panels provided sufficient information to differentiate between peri-implantitis and healthy implants within both cohorts independently (Fig. 6B). Across these panels are eight proteins significantly upregulated and 21 proteins significantly downregulated in peri-implantitis (Fig. 6A).
[0206] Three panels were confirmed by high-performance classification models with ROC AUC values > 0.90 in the external validation cohort. These panels include growth factor receptor-binding protein 2 (GRB2), in combination with either argininosuccinatesynthase (ASS1), serpinB5 (SERPINB5), or tumor-associated calcium signal transducer 2 (TACSTD2), all of which were found significantly changed when comparing the protein abundance in healthy implant and peri-implantitis samples in all cohorts (Fig. 6C).
[0207] Table 4: Additional preferred enriched or upregulated sulcus-protein markers or depleted or downregulated sulcus-protein markers in peri-implantitis vs healthy implant as identified in the context of the present invention
[0208] Uniprot IDs Genes
[0209] (Database Status 05 / 2026)
[0210] enriched or upregulated markers
[0211] P04040 CAT
[0212] P35754 GLRX
[0213] 060234 GMFG
[0214] P62993 GRB2
[0215] Q6ZS72 PEAK3
[0216] 075594 PGLYRP1
[0217] 075368 SHBGRL
[0218] Q15819 UBE2V2
[0219] depleted or downregulated markers
[0220] P30838 ALDH3A1
[0221] P13928 ANXA8
[0222] P00966 ASS1
[0223] Q9NYQ8 FAT2
[0224] Q9Y6R7 FCGBP
[0225] Q7Z7M9 GALNT5
[0226] P28799 GRN
[0227] Q16787 LAMA3
[0228] Q13753 LAMC2
[0229] P22079 LPO
[0230] Q969L2 MAL2
[0231] P39900 MMP12
[0232] P19021 PAM
[0233]
[0234] P62899 RPL31
[0235] P62266 RPS23
[0236] P62854 RPS26
[0237] P36952 SERPINB5
[0238] P03973 SLPI
[0239] 043278 SPINT1
[0240] P09758 TACSTD2
[0241] Q86T26 TMPRSS11B
[0242]
[0243] Based on the 51 two-protein panels that yielded ROC AUC values > 0.90 in both cohorts, i.e., each of these panels provided sufficient information to differentiate between peri-implantitis and healthy implants within both cohorts independently, preferred marker combinations are as follows:
[0244] CAT + GRN, GALNT5, or LAMC2,
[0245] GLRX + LAMC2, or SLPI,
[0246] GMFG + FAT2, LAMC2, or SLPI,
[0247] GRB2 + ALDH3A1, ANXA8, ASS1, FAT2, FCGBP, GALNT5, GRN, PEAK3, LAMA3, LAMC2, LPO, MAL2, PAM, RPL31, RPS23, SERPINB5, SLPI, SPINT1, or TACSTD2,
[0248] PEAK3 + ANXA8, FAT2, LAMC2, SLPI, or TACSTD2,
[0249] PGLYRP1 + GALNT5, LAMC2, MMP12, RPS26, or TACSTD2,
[0250] SHBGRL + FAT2, FCGBP, MAL2, TMPRSS1 IB, or SPINT1,
[0251] UBE2V2 + ANXA8, FAT2, FCGBP, GALNT5, GRN, LAMA3, or TACSTD2, ALDH3A1 + PGLYRP1, and
[0252] ANXA8 + GMFG.
[0253] Literature as cited
[0254] Ahadi, Sara; Zhou, Wenyu; Schussler-Fiorenza Rose, Sophia Miryam; Sailani, M. Reza; Contrepois, Kevin; Avina, Monika et al. (2020): Personal aging markers and ageotypes revealed by deep longitudinal profiling. In: Nature medicine 26 (1), pp. 83-90. DOI: 10.1038 / s41591-019-0719-5.
[0255] Alassiri, Saeed; Pamanen, Pirjo; Rathnayake, Nilminie; Johannsen, Gunnar; Heikkinen, Anna-Maria; Lazzara, Richard et al. (2018): The Ability of Quantitative, Specific, andSensitive Point-of-Care / Chair-Side Oral Fluid Immunotests for aMMP-8 to Detect Periodontal and Peri-Implant Diseases. In: Disease markers 2018, p. 1306396. DOI: 10.1155 / 2018 / 1306396.
[0256] Alassy, Hatem; Parachuru, Praveen; Wolff, Larry (2019): Peri-Implantitis Diagnosis and Prognosis Using Biomarkers in Peri-Implant Crevicular Fluid: A Narrative Review. In: Diagnostics (Basel, Switzerland) 9 (4). DOI: 10.3390 / diagnostics9040214.
[0257] Albrektsson, Tomas; Canullo, Luigi; Cochran, David; Bruyn, Hugo de (2016): "Peri-Implantitis": A Complication of a Foreign Body or a Man-Made "Disease". Facts and Fiction. In: Clinical implant dentistry and related research 18 (4), pp. 840-849. DOI: 10.1111 / cid.12427.
[0258] Andrucioli, Marcela Cristina Damiao; Matsumoto, Mirian Aiko Nakane; Fukada, Sandra Yasuyo; Saraiva, Maria Conceigao Pereira; Bergamo, Ana Zilda Nazar; Romano, Fabio Lourengo et al. (2019): Quantification of pro-inflammatory cytokines and osteoclastogenesis markers in successful and failed orthodontic mini-implants. In: Journal of applied oral science: revista FOB 27, e20180476. DOI: 10.1590 / 1678-7757-2018-0476.
[0259] Arakawa, Hikaru; Uehara, Junji; Hara, Emilio Satoshi; Sonoyama, Wataru; Kimura, Aya; Kanyama, Manabu et al. (2012): Matrix metalloproteinase-8 is the major potential collagenase in active peri-implantitis. In: Journal of prosthodontic research 56 (4), pp.
[0260] 249-255. DOI: 10.1016 / j.jpor.2012.07.002.
[0261] Arias-Bujanda, Nora; Regueira-Iglesias, Alba; Balsa-Castro, Carlos; Nibali, Luigi; Donos, Nikos; Tomas, Inmaculada (2019): Accuracy of single molecular biomarkers in gingival crevicular fluid for the diagnosis of periodontitis: A systematic review and metaanalysis. In: Journal of clinical periodontology 46 (12), pp. 1166-1182. DOI: 10.1111 / jcpe.13188.
[0262] Arumugam, Thiruvengadam; Simeone, Diane M.; Schmidt, Ann Marie; Logsdon, Craig D. (2004): SI OOP stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). In: The Journal of biological chemistry 279 (7), pp.
[0263] 5059-5065. DOI: 10.1074 / jbc.M310124200.
[0264] Baliban, Richard C.; Sakellari, Dimitra; Li, Zukui; DiMaggio, Peter A.; Garcia, Benjamin A.; Floudas, Christodoulos A. (2012): Novel protein identification methods for biomarker discovery via a proteomic analysis of periodontally healthy and diseased gingivalcrevicular fluid samples. In: Journal of clinical periodontology, pp. 203-212. DOI: 10.1111 / j.1600-051X.2011.01805.x.
[0265] Bao, Kai; Li, Xiaofei; Kajikawa, Tetsuhiro; Toshiharu, Abe; Selevsek, Nathalie; Grossmann, Jonas et al. (2020): Pressure Cycling Technology Assisted Mass Spectrometric Quantification of Gingival Tissue Reveals Proteome Dynamics during the Initiation and Progression of Inflammatory Periodontal Disease. In: Proteomics 20 (3-4), el900253. DOI: 10.1002 / pmic.201900253.
[0266] Basegm ez, Cansu; Yalcin, Serdar; Yalcin, Funda; Ersanli, Selim; Mijiritsky, Eitan (2012): Evaluation of peri-implant crevicular fluid prostaglandin E2 and matrix metalloproteinase-8
[0267] levels from health to peri-implant disease status: a prospective study. In: Implant dentistry 21 (4), pp. 306-310. DOI: 10.1097 / ID.0b013e3182588408.
[0268] Berglundh, Tord; Armitage, Gary; Araujo, Mauricio G.; Avila-Ortiz, Gustavo; Blanco, Juan; Camargo, Paulo M. et al. (2018): Peri-implant diseases and conditions: Consensus report of workgroup 4 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. In: Journal of periodontology 89 Suppl 1, S313-S318. DOI: 10.1002 / JPER.17-0739.
[0269] Bostanci, N.; Bao, K.; Wahlander, A.; Grossmann, J.; Thurnheer, T.; Belibasakis, G. N. (2015): Secretome of gingival epithelium in response to subgingival biofilms. In: Molecular oral microbiology, pp. 323-335. DOI: 10.1111 / omi.12096.
[0270] Bostanci, N.; Heywood, W.; Mills, K.; Parkar, M.; Nibali, L.; Donos, N. (2010): Application of label-free absolute quantitative proteomics in human gingival crevicular fluid by LC / MS E (gingival exudatome). In: Journal of proteome research 9 (5), pp.
[0271] 2191-2199. DOI: 10.1021 / pr900941z.
[0272] Bruderer, Roland; Bernhardt, Oliver M.; Gandhi, Tejas; Miladinovic, Sasa M.; Cheng, Lin-Yang; Messner, Simon et al. (2015): Extending the limits of quantitative proteome profiling with data-independent acquisition and application to acetaminophen-treated three-dimensional liver microtissues. In: Molecular & cellular proteomics : MCP 14 (5), pp. 1400-1410. DOI: 10.1074 / mcp.Ml 14.044305.
[0273] Campanelli, D.; Detmers, P. A.; Nathan, C. F.; Gabay, J. E. (1990): Azurocidin and a homologous serine protease from neutrophils. Differential antimicrobial and proteolytic properties. In: The Journal of clinical investigation 85 (3), pp. 904-915. DOI: 10.1172 / JCI114518.Canullo, Luigi; Schlee, Markus; Wagner, Wilfried; Covani, Ugo (2015): International Brainstorming Meeting on Etiologic and Risk Factors of Peri-implantitis, Montegrotto (Padua, Italy), August 2014. In: The International journal of oral & maxillofacial implants 30 (5), pp. 1093-1104. DOI: 10.11607 / jomi.4386.
[0274] Carcuac, O.; Berglundh, T. (2014): Composition of human peri-implantitis and periodontitis lesions. In: Journal of dental research 93 (11), pp. 1083-1088. DOI: 10.1177 / 0022034514551754.
[0275] Carcuac, Olivier; Derks, Jan; Abrahamsson, Ingemar; Wennstrom, Jan L.; Berglundh, Tord (2020): Risk for recurrence of disease following surgical therapy of peri-implantitis-A prospective longitudinal study. In: Clinical oral implants research 31 (11), pp. 1072- 1077. DOI: 10.111 l / clr.13653.
[0276] Demichev, Vadim; Messner, Christoph B.; Vernardis, Spyros I.; Lilley, Kathryn S.; Raiser, Markus (2020): DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. In: Nature methods 17 (1), pp. 41-44. DOI: 10.1038 / s41592-019-0638-x.
[0277] Derks, Jan; Schaller, Dennis; Hakansson, Jan; Wennstrom, Jan L.; Tomasi, Cristiano; Berglundh, Tord (2016): Peri-implantitis - onset and pattern of progression. In: Journal of clinical periodontology 3 (4), pp. 383-388. DOI: 10.1111 / jcpe.12535.
[0278] Duarte, P. M.; Serrao, C. R.; Miranda, T. S.; Zanatta, L. C. S.; Bastos, M. F.; Faveri, M. et al. (2016): Could cytokine levels in the peri-implant crevicular fluid be used to distinguish between healthy implants and implants with peri-implantitis? A systematic review. In: Journal of periodontal research 51 (6), pp. 689-698. DOI: 10.1111 / jre.12354. Durrani, Farhan; Singh, Royana (2015): Myeloperoxidase level around dental implants as an indicator of an inflammatory process. In: Indian journal of dentistry 6 (1), pp. 2-6. DOI: 10.4103 / 0975-962X.151688.
[0279] Esberg, Anders; Isehed, Catrine; Holmlund, Anders; Lundberg, Pernilla (2019): Periimplant crevicular fluid proteome before and after adjunctive enamel matrix derivative treatment of peri-implantitis. In: Journal of clinical periodontology 46 (6), pp. 669-677. DOI: 10.1111 / jcpe.13108.
[0280] Esposito, Marco; Grusovin, Maria Gabriella; Worthington, Helen V. (2012): Treatment of peri-implantitis: what interventions are effective? A Cochrane systematic review. In: European journal of oral implantology 5 Suppl, S21-41.Fahrner, Matthias; Kook, Lucas; Frohlich, Klemens; Biniossek, Martin L.; Schilling, Oliver (2021): A Systematic Evaluation of Semispecific Peptide Search Parameter Enables Identification of Previously Undescribed N-Terminal Peptides and Conserved Proteolytic Processing in Cancer Cell Lines. In: Proteomes 9 (2). DOI: 10.3390 / proteomes9020026.
[0281] Fretwurst, T.; Nelson, K.; Tamow, D. P.; Wang, H-L; Giannobile, W. V. (2018): Is Metal Particle Release Associated with Peri-implant Bone Destruction? An Emerging Concept. In: Journal of dental research 97 (3), pp. 259-265. DOI: 10.1177 / 0022034517740560. Fretwurst, Tobias; Buzanich, Guenter; Nahles, Susanne; Woelber, Johan Peter; Riesemeier, Heinrich; Nelson, Katja (2016): Metal elements in tissue with dental peri-implantitis: a pilot study. In: Clinical oral implants research 27 (9), pp. 1178-1186. DOI: 10.111 l / clr.12718.
[0282] Fretwurst, Tobias; Garaicoa-Pazmino, Carlos; Nelson, Katja; Giannobile, William V.; Squarize, Cristiane H.; Larsson, Lena; Castilho, Rogerio M. (2020): Characterization of macrophages infiltrating peri-implantitis lesions. In: Clinical oral implants research 31 (3), pp. 274-281. DOI: 10.1111 / clr.13568.
[0283] Fretwurst, Tobias; Muller, Janina; Larsson, Lena; Bronsert, Peter; Hazard, Derek; Castilho, Rogerio M. et al. (202): Immunohistological composition of peri-implantitis affected tissue around ceramic implants - A pilot study. In: Journal of periodontology. DOI: 10.1002 / JPER.20-0169.
[0284] Furtmuller, P. G.; Burner, U.; Obinger, C. (1998): Reaction of myeloperoxidase compound I with chloride, bromide, iodide, and thiocyanate. In: Biochemistry 37 (51), pp. 17923-17930. DOI: 10.102 l / bi9818772.
[0285] Gianazza, Elisabetta; Miller, Ingrid; Palazzolo, Luca; Parravicini, Chiara; Eberini, Ivano (2016): With or without you - Proteomics with or without major plasma / serum proteins. In: Journal of proteomics 140, pp. 62-80. DOI: 10.1016 / j.jprot.2016.04.002.
[0286] Gillet, Ludovic C.; Navarro, Pedro; Tate, Stephen; Rost, Hannes; Selevsek, Nathalie; Reiter, Lukas et al. (2012): Targeted data extraction of the MS / MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. In: Molecular & cellular proteomics : MCP 11 (6), 0111.016717. DOI: 10.1074 / mcp.0111.016717.
[0287] Gtirlek, Onder; Gurmi§, Pinar; Nile, Christopher J.; Lappin, David F.; Buduneli, Nurcan (2017): Biomarkers and Bacteria Around Implants and Natural Teeth in the SameIndividuals. In: Journal of periodontology 88 (8), pp. 752-761. DOI: 10.1902 / jop.2017.160751.
[0288] Iglhaut, Gerhard; Salomon, Sebastian; Fretwurst, Tobias; Thomas, Peter; Endres, Janina; Kessler, Selina; Summer, Burkhard (2021): Cross-sectional evaluation of clinical and immunological parameters at partially microgrooved vs machined abutments in humans. In: International journal of implant dentistry 7 (1), p. 46. DOI: 10.1186 / s40729-021-00329-8.
[0289] Jiang, Hongfei; Hu, Hang; Tong, Xiaomei; Jiang, Qiuhong; Zhu, Haiyan; Zhang, Songying (2012): Calcium-binding protein SIOOP and cancer: mechanisms and clinical relevance. In: Journal of cancer research and clinical oncology 138 (1), S. 1-9. DOI: 10.1007 / s00432-011-1062-5.
[0290] Jiang, Lihua; Wang, Meng; Lin, Shin; Jian, Ruiqi; Li, Xiao; Chan, Joanne et al. (2020): A Quantitative Proteome Map of the Human Body. In: Cell 183 (1), 269-283. el9. DOI: 10.1016 / j.cell.2020.08.036.
[0291] Karatas, Ozkan; Balci Yuce, Hatice; Taskan, Mehmet Murat; Gevrek, Fikret; Lafci, Emre; Kasap, Hayrunnisa (2020): Histological evaluation of peri-implant mucosal and gingival tissues in peri-implantitis, peri-implant mucositis and periodontitis patients: a cross-sectional clinical study. In: Acta Odontologica Scandinavica 78 (4), pp. 241-249. DOI: 10.1080 / 00016357.2019.1691256.
[0292] Kelstrup, Christian D.; Bekker-Jensen, Dorte B.; Arrey, Tabiwang N.; Hogrebe, Alexander; Harder, Alexander; Olsen, Jesper V. (2018): Performance Evaluation of the Q Exactive HF-X for Shotgun Proteomics. In: Journal of proteome research 17 (1), pp.
[0293] 727-738. DOI: 10.1021 / acs.jproteome.7b00602.
[0294] Kensara, Anmar; Hefni, Eman; Williams, Mary Ann; Saito, Hanae; Mongodin, Emmanuel; Masri, Radi (2021): Microbiological Profile and Human Immune Response Associated with Peri-implantitis: A Systematic Review. In: Journal of prosthodontics : official journal of the American College of Prosthodontists 30 (3), pp. 210-234. DOI: 10.1111 / j opr.13270.
[0295] Khosla, S. (2001): Minireview: the OPG / RANKL / RANK system. In: Endocrinology 142 (12), pp. 5050-5055. DOI: 10.1210 / endo.l42.12.8536.
[0296] Korkmaz, Brice; Horwitz, Marshall S.; Jenne, Dieter E.; Gauthier, Francis (2010): Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. In: Pharmacological reviews 62 (4), pp. 726-759. DOI: 10.1124 / pr.l 10.002733.Krakauer, Teresa (2008): Nuclear factor-kappaB : fine-tuning a central integrator of diverse biologic stimuli. In: International reviews of immunology 27 (5), pp. 286-292. DOI: 10.1080 / 08830180802317957.
[0297] Krauspe, Vanessa; Fahrner, Matthias; Spat, Philipp; Steglich, Claudia; Frankenberg-Dinkel, Nicole; Macek, Boris et al. (2021): Discovery of a small protein factor involved in the coordinated degradation of phycobilisomes in cyanobacteria. In: Proceedings of the National Academy of Sciences of the United States of America 118 (5). DOI: 10.1073 / pnas.2012277118.
[0298] Kwon, Ho Jeong; Fehniger, Thomas E.; Marko-Varga, Gy orgy (2016): Building the basis for proteomics in personalized medicine for targeted treatment. In: Clinical and translational medicine 5 (1), p. 19. DOI: 10.1186 / s40169-016-0096-3.
[0299] Lafaurie, Gloria Ines; Sabogal, Maria Alejandra; Castillo, Diana Marcela; Rincon, Maria Victoria; Gomez, Luz Amparo; Lesmes, Yamil Augusto; Chambrone, Leandro (2017): Microbiome and Microbial Biofilm Profiles of Peri-Implantitis: A Systematic Review. In: Journal of periodontology 88 (10), pp. 1066-1089. DOI: 10.1902 / jop.2017.170123. Le Tourneau, Christophe; Borcoman, Edith; Kamal, Maud (2019): Molecular profiling in precision medicine oncology. In: Nature medicine 25 (5), pp. 711-712. DOI: 10.1038 / s41591-019-0442-2.
[0300] Loos, Bruno G.; Tjoa, Stanley (2005): Host-derived diagnostic markers for periodontitis: do they exist in gingival crevice fluid? In: Periodontology 2000 39, pp. 53-72. DOI: 10.1111 / j.1600-0757.2005.00129.x.
[0301] Ludwig, Christina; Gillet, Ludovic; Rosenberger, George; Amon, Sabine; Collins, Ben C.; Aebersold, Ruedi (2018): Data-independent acquisition-based SWATH-MS for quantitative proteomics: a tutorial. In: Molecular systems biology 14 (8), e8126. DOI: 10.15252 / msb.20178126.
[0302] Marinho, Marcelo C.; Pacheco, Ana Beatriz F.; Costa, Giovani C. V.; Ortiz, Nina D.; Zajdenverg, Lenita; Sansone, Carmelo (2019): Quantitative gingival crevicular fluid proteome in type 2 diabetes mellitus and chronic periodontitis. In: Oral diseases 25 (2), pp. 588-595. DOI: 10.1111 / odi.12996.
[0303] Maxeiner, Sebastian; Shi, Nian; Schalla, Carmen; Ay din, Guelcan; Hoss, Mareike; Vogel, Simon et al. (2015): Crucial role for the LSPl-myosinle bimolecular complex in the regulation of Fey receptor-driven phagocytosis. In: Molecular biology of the cell 26 (9), pp. 1652-1664. DOI: 10.1091 / mbc.E14-05-1005.Mombelli, Andrea; Decaillet, Fabien (2011): The characteristics of biofilms in periimplant disease. In: Journal of clinical periodontology 38 Suppl 11, pp. 203-213. DOI: 10.1 lll / j.l600-051X.2010.01666.x.
[0304] Nalmpantis, Dimitrios; Gatou, Asimina; Fragkioudakis, loannis; Margariti, Apostolia; Skoura, Lemonia; Sakellari, Dimitra (2020): Azuroci din in gingival crevicular fluid as a potential biomarker of chronic periodontitis. In: Journal of periodontal research 55 (2), pp. 209-214. DOI: 10.1111 / jre.12703.
[0305] Nguyen, Trang; Sedghi, Lea; Ganther, Sean; Malone, Erin; Kamarajan, Pachiyappan; Kapila, Yvonne L. (2020): Host-microbe interactions: Profiles in the transcriptome, the proteome, and the metabolome. In: Periodontology 2000 82 (1), pp. 115-128. DOI: 10.1111 / prd.12316.
[0306] Palanissami, Gowri; Paul, Solomon F. D. (2018): RAGE and Its Ligands: Molecular Interplay Between Glycation, Inflammation, and Hallmarks of Cancer-a Review. In: Hormones & cancer 9 (5), pp. 295-325. DOI: 10.1007 / sl2672-018-0342-9.
[0307] Persson, G. Rutger; Renvert, Stefan (2014): Cluster of bacteria associated with peri-implantitis. In: Clinical implant dentistry and related research 16 (6), pp. 783-793. DOI: 10.1111 / cid.12052.
[0308] Rakic, Mia; Lekovic, Vojislav; Nikolic-Jakoba, Natasa; Vojvodic, Danilo; Petkovic-Curcin, Aleksandra; Sanz, Mariano (2013): Bone loss biomarkers associated with peri-implantitis. A cross-sectional study. In: Clinical oral implants research 24 (10), pp. 1110- 1116. DOI: 10.1111 / j.1600-0501.2012.02518.x.
[0309] Ramanauskaite, Ausra; Fretwurst, Tobias; Schwarz, Frank (2021): Efficacy of alternative or adjunctive measures to conventional non-surgical and surgical treatment of periimplant mucositis and peri-implantitis: a systematic review and m eta-analysis. In: International journal of implant dentistry 7 (1), p. 112. DOI: 10.1186 / s40729-021-00388-x.
[0310] Renvert, Stefan; Roos-Jansaker, Anne-Marie; Lindahl, Christel; Renvert, Helena; Rutger Persson, G. (2007): Infection at titanium implants with or without a clinical diagnosis of inflammation. In: Clinical oral implants research 18 (4), pp. 509-516. DOI: 10.111 l / j.1600-0501.2007.01378.x.
[0311] Ritchie, Matthew E.; Phipson, Belinda; Di Wu; Hu, Yifang; Law, Charity W.; Shi, Wei; Smyth, Gordon K. (2015): limma powers differential expression analyses for RNA-sequencing and microarray studies. In: Nucleic acids research 43 (7), e47. DOI: 10.1093 / nar / gkv007.
[0312] Rizal, Muhammad Ihsan; Soeroso, Yuniarti; Sulijaya, Benso; Assiddiq, Bobby F.; Bachtiar, Endang W.; Bachtiar, Boy M. (2020): Proteomics approach for biomarkers and diagnosis of periodontitis: systematic review. In: Heliyon 6 (6), e04022. DOI: 10.1016 / j.heliyon.2020.e04022.
[0313] Sahrmann, Philipp; Gilli, Fabienne; Wiedemeier, Daniel B.; Attin, Thomas; Schmidlin, Patrick R.; Karygianni, Lamprini (2020): The Microbiome of Peri-Implantitis: A Systematic Review and Meta- Analysis. In: Microorganisms 8 (5). DOI: 10.3390 / microorganisms8050661.
[0314] Salazar, Manuela Gesell; Jehmlich, Nico; Murr, Annette; Dhople, Vishnu M.; Holtfreter, Birte; Hammer, Elke et al. (2013): Identification of periodontitis associated changes in the proteome of whole human saliva by mass spectrometric analysis. In: Journal of clinical periodontology 40 (9), pp. 825-832. DOI: 10.1111 / jcpe.12130.
[0315] Scharinger, Katja; Maxeiner, Sebastian; Schalla, Carmen; Riitten, Stephan; Zenke, Martin; Sechi, Antonio (2021): LSPl-myosinle bimolecular complex regulates focal adhesion dynamics and cell migration. In: FASEB journal : official publication of the Federation of American Societies for Experimental Biology 35 (2), e21268. DOI: 10.1096 / fj.202000740RR.
[0316] Schwarz, Frank (2016): A WMF guideline "Peri-implant infections on dental implants, treatment" 2016.
[0317] Shin, Myung-Seop; Kim, Yun-Gon; Shin, Yoo Jin; Ko, Byoung Joon; Kim, Sungtae; Kim, Hyun-Duck (2019): Deep sequencing salivary proteins for periodontitis using proteomics. In: Clinical oral investigations, pp. 3571-3580. DOI: 10.1007 / s00784-018-2779-1.
[0318] Sorsa, Timo; Gieselmann, Dirk; Arweiler, Nicole B.; Hernandez, Marcela (2017): A quantitative point-of-care test for periodontal and dental peri-implant diseases. In: Nature reviews. Disease primers 3, p. 17069. DOI: 10.1038 / nrdp.2017.69.
[0319] Sorsa, Timo; Gursoy, Ulvi K.; Nwhator, Solomon; Hernandez, Marcela; Tervahartiala, Taina; Leppilahti, Jussi et al. (2016): Analysis of matrix metalloproteinases, especially MMP-8, in gingival crevicular fluid, mouthrinse and saliva for monitoring periodontal diseases. In: Periodontology 200070 (1), pp. 142-163. DOI: 10.1111 / prd.12101.Tholander, Fredrik; Muroya, Ayumo; Roques, Bernard-Pierre; Fournie-Zaluski, Marie-Claude; Thunnissen, Marjolein M. G. M.; Haeggstrbm, Jesper Z. (2008): Structure-based dissection of the active site chemistry of leukotriene A4 hydrolase: implications for Ml aminopeptidases and inhibitor design. In: Chemistry & biology 15 (9), pp. 920-929. DOI: 10.1016 / j.chembiol.2008.07.018.
[0320] Wang, Chin-Wei; Hao, Yuning; Di Gianfilippo, Riccardo; Sugai, James; Li, Jiaqian; Gong, Wang et al. (2021): Machine learning-assisted immune profiling stratifies peri-implantitis patients with unique microbial colonization and clinical outcomes. In: Theranostics 11 (14), pp. 6703-6716. DOI: 10.7150 / thno.57775.
[0321] Wang, Hom-Lay; Garaicoa-Pazmino, Carlos; Collins, Amy; Ong, Hwen-Sei; Chudri, Rini; Giannobile, William V. (2016): Protein biomarkers and microbial profiles in peri-implantitis. In: Clinical oral implants research 27 (9), pp. 1129-1136. DOI: 10.1111 / clr.12708.
[0322] Wasiluk, K. R.; Skubitz, K. M.; Gray, B. H. (1991): Comparison of granule proteins from human polymorphonuclear leukocytes which are bactericidal toward Pseudomonas aeruginosa. In: Infection and immunity 59 (11), pp. 4193-4200. DOI: 10.1128 / iai.59.11.4193-4200.1991.
Claims
CLAIMS1. A method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant, comprising detecting, and quantifying at least one protein marker in a sulcus fluid sample obtained from said subject that is enriched or upregulated or depleted or downregulated in the sample when compared to a sulcus fluid sample i) obtained from a healthy subject (H), ii) an earlier sulcus fluid sample taken from said subject, and / or iii) to a control sample,wherein an enrichment or upregulation of at least one protein marker selected from the group consisting of PGLYRP1, UBE2V2, and GRB2,or a depletion or downregulation of at least one protein marker selected from the group consisting of BPIFB2, LAMC2, ITGA6, and LAMA3,or a group of protein markers selected from the group consisting ofLAMA3 in combination with at least one of BPI, GCA, GLRX, PEAK3, PRTN3, RAP1B, SHBGRL (SH3BGRL), and UBE2V2;GCA in combination with at least one of ITGA6, LAMC2, MUC7, and PAM;GLRX in combination with at least one of CST1, FCGBP, MGP, PAM, and SLPI; LAMC2 in combination with at least one of CAT, and GLRX;PAM in combination with at least one of GRB2, and RAP IB; andPGLYRP1 in combination with at least one of BPIFB2, GALNT5, LAMC2, MMP12, RPS26, and TACSTD2;CAT in combination with at least one of GRN, and GALNT5;GMFG in combination with at least one of FAT2, LAMC2, and SLPI;GRB2 in combination with at least one of ALDH3A1, ANXA8, ASS1, FAT2, FCGBP, GALNT5, GRN, PEAK3, LAMA3, LAMC2, LPO, MAL2, PAM, RPL31, RPS23, SERPINB5, SLPI, SPINT1, and TACSTD2;PEAK3 in combination with at least one of ANXA8, FAT2, LAMC2, SLPI, and TACSTD2;SHBGRL in combination with at least one of FAT2, FCGBP, MAL2, TMPRSS1 IB, and SPINT1;UBE2V2 in combination with at least one of ANXA8, FAT2, FCGBP, GALNT5, GRN, LAMA3, and TACSTD2;ALDH3A1 in combination with PGLYRP1, andANXA8 in combination with GMFGdetects a PI in said subject.
2. Method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant according to claim 1, wherein an enrichment or upregulation of at least one protein marker selected from the group consisting of BPI, CAT, GCA, GRB2, GLRX, GFMG, PEAK3, PGLYP1, PRTN3, RAP1B, SHBGRL (SH3BGRL), and UBE2V2 or a depletion or downregulation of at least one protein marker selected from the group consisting of ALDH3A1, ANXA8, ASS1, FAT2, FCGBP, GALNT5, GRN, LPO, MAL2, MMP12, PAM, BPIFB2, ITGA6, LAMA3, RPS23, RPS26, SERPINB5, SLPI, SPINT1, TACSTD2, TMPRSS1 IB, and LAMC2 detects a PI in said subject when compared to a sulcus fluid sample obtained from a healthy implant (I), orwherein an enrichment or upregulation of at least one protein marker selected from the group consisting of CAT, GLRX, GRB2, SHBGRL, and UBE2V2 or a depletion or downregulation of at least one protein marker selected from the group consisting of BPIFB2, ITGA6, LAMA3, LAMC2, and PAM detects a PI in said subject when compared to a sulcus fluid sample obtained from a healthy tooth (T).
3. Method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant according to claim 1 or 2, wherein the significance of the at least one protein marker has a moderated or adjusted p-value of< 0.05, and / or a significance of an AUC >0.80.
4. Method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant according to any one of claims 1 to 3, wherein the sulcus fluid sample was obtained from said subject using sterile paper strips such as, for example, are endodontic paper points or periopapers.
5. The method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant according to any one of claims 1 to 4, wherein the detection and quantification of the at least one protein in the sample comprises a method selected from at least one of ELISA, bicinchoninic acid assay, and mass spectrometry.
6. The method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant according to any one of claims 1 to 5, further comprising detecting endogenous proteolysis in the sample, wherein a higher endogenous proteolytic activity as detected when compared to a non-PI sample, an I sample, a T sample, and / or a control H sample indicates a PI sample, wherein preferably detecting a higher endogenous proteolytic activity comprises detecting of proportional intensities of semi-specific peptides.
7. The method for detecting peri-implantitis (PI) in a mammalian subject having a tooth implant according to any one of claims 1 to 6, wherein the mammalian subject is selected from a cat, dog, mouse, rat, horse, sheep, goat, monkey, cow, or human, preferably a human.
8. A method for diagnosing the status of peri-implantitis (PI) in a mammalian subject having a tooth implant, comprising performing the method according to any one of claims 1 to 7, and diagnosing an exacerbated state of the PI if the at least one protein in the sulcus fluid sample obtained from said subject is further enriched or further depleted in the sample when compared to an earlier sulcus fluid sample obtained from the subject.
9. A method for identifying a compound that is active against PI, comprising the steps of: a) providing at least one candidate compound with a subject suffering from PI, and b) performing the method according to any one of claims 1 to 7, wherein a lower enrichment and / or a lower depletion of at least one protein in the sulcus fluid sample in the presence of said candidate compound, when compared to the absence of said candidate compound, identifies a compound that is active against PI.
10. The method for identifying a compound that is active against PI according to claim 9, wherein the candidate compound is selected from the group consisting of a chemical molecule, a molecule selected from a library of small organic molecules, a molecule selected from a combinatory library, a cell extract, in particular a plant cell extract, a small molecular drug, a protein, a protein fragment, a molecule selected from a peptide library, and an antibody or fragment thereof.
11. A compound that is active against PI as identified according to a method according to claim 9 or 10, or a pharmaceutical composition comprising said compound that is active against PI, together with a pharmaceutically acceptable carrier.
12. A method for monitoring of a treatment or prophylaxis against PI in a mammalian subject in need thereof, comprising a) providing a treatment or prophylaxis against PI to said subject, comprising administering to said subject a compound or pharmaceutical composition that is active against PI, preferably a compound or pharmaceutical composition according to claim 11, b) performing the method according to any one of claims 1 to 7 on a biological sample obtained from said subject, and c) comparing the enrichment and / or depletion of at least one protein in the sulcus fluid sample as detected with the enrichment and / or depletion of the at least one protein in an earlier sulcus fluid sample taken from said subject, and / or to a control (H) sample.
13. The compound that is active against PI or the pharmaceutical composition comprising said compound that is active against PI according to claim 11 for use in the prevention or treatment of PI in a subject.
14. A diagnostic or therapeutic kit comprising materials for performing a method according to any one of claims 1 to 10 or 12 in one or separate containers, optionally together with auxiliary agents, a compound that is active against PI as identified according to a method according to claim 9 or 10, and / or instructions for performing said method.
